Completed PHASE2 INTERVENTIONAL 2-arm NCT01650389

Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination (MVA(TB)029)

Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV Infected Mothers

Sponsor: Department for International Development, United Kingdom

Conditions HIV Tuberculosis

Interventions BCG Vaccine SSI Candin MVA85A

Updated 5 times since 2017 Last updated: Sep 29, 2015 Started: Oct 31, 2012 Primary completion: May 31, 2015 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01650389, this PHASE2 trial focuses on HIV and Tuberculosis and remains completed. Sponsored by Department for International Development, United Kingdom, it has been updated 5 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Department for International Development, United Kingdom
Mark Hatherill
Medical Research Council
Oxford-Emergent Tuberculosis Consortium
University of Oxford
University of Stellenbosch
Wellcome Trust

Data source: University of Cape Town

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Khayelitsha, South Africa
• Worcester, South Africa